UCB encouraged by novel lupus therapy
This article was originally published in Scrip
Executive Summary
UCBhas presented proof-of-concept data for epratuzumab, a novel humanised anti-CD22 antibody, showing a reduction in disease activity and reduced reliance on corticosteroids in patients with severe systemic lupus (SLE), compared with placebo.